1620 Investment Advisors Inc. Sells 1,093 Shares of Pfizer Inc. (NYSE:PFE)

1620 Investment Advisors Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 5.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,091 shares of the biopharmaceutical company’s stock after selling 1,093 shares during the quarter. 1620 Investment Advisors Inc.’s holdings in Pfizer were worth $480,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Sector Gamma AS raised its position in Pfizer by 40.9% in the 4th quarter. Sector Gamma AS now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $30,642,000 after purchasing an additional 335,000 shares during the last quarter. Lakeshore Financial Planning Inc. bought a new position in Pfizer in the 4th quarter valued at $327,000. Wayfinding Financial LLC bought a new stake in shares of Pfizer during the fourth quarter worth $214,000. Goodman Financial Corp raised its position in shares of Pfizer by 5.5% during the fourth quarter. Goodman Financial Corp now owns 432,271 shares of the biopharmaceutical company’s stock worth $11,468,000 after acquiring an additional 22,609 shares during the last quarter. Finally, DCF Advisers LLC raised its position in shares of Pfizer by 49.5% during the fourth quarter. DCF Advisers LLC now owns 51,350 shares of the biopharmaceutical company’s stock worth $1,362,000 after acquiring an additional 17,000 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday. Finally, Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 0.2 %

PFE stock opened at $26.17 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $148.29 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61. The business has a 50-day moving average of $26.18 and a 200-day moving average of $27.07. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.